{
    "nct_id": "NCT03701334",
    "official_title": "A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)",
    "inclusion_criteria": "* Patient is ≥ 18 years-old at the time of PICF signature\n* Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male.\n* Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization.\n* Patient has breast cancer that is positive for ER and/or PgR\n* Patient has HER2-negative breast cancer\n* Patient has available archival tumor tissue from the surgical specimen\n* Patient after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories: anatomic stage group II or III\n* If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines\n* If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines\n* Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Patient has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for 5 years\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient has received any CDK4/6 inhibitor\n* Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk (\"chemoprevention\") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement therapy.\n* Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin.\n* Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET\n* Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.\n* Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET\n* Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization\n* Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies\n* Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization\n* Patient has known HIV infection, Hepatitis B or C infection\n* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality\n* Patient is currently receiving any of the following substances within 7 days before randomization - Concomitant medications, herbal supplements, and/or fruits that are known as strong inhibitors or inducers of CYP3A4/5 or Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\n* is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting trial treatment\n* Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments\n* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol\n* Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial.\n* Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial",
    "miscellaneous_criteria": ""
}